دورية أكاديمية
The Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Serum Irisin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
| العنوان: | The Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Serum Irisin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. |
|---|---|
| المؤلفون: | Ansari S; Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, IR Iran., Djalali M; Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, IR Iran., Mohammadzadeh Honarvar N; Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, IR Iran., Mazaherioun M; Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, International Campus, Tehran University of Medical Sciences, Tehran, IR Iran., Zarei M; Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, IR Iran., Agh F; Faculty of Nutritional Sciences and Dietetics, Iran University of Medical Sciences, Tehran, IR Iran., Gholampour Z; Farahzad Health Care Center, Iran University of Medical Sciences, Tehran, IR Iran., Javanbakht MH; Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, IR Iran. |
| المصدر: | International journal of endocrinology and metabolism [Int J Endocrinol Metab] 2017 Jan 21; Vol. 15 (1), pp. e40614. Date of Electronic Publication: 2017 Jan 21 (Print Publication: 2017). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Brieflands Country of Publication: Netherlands NLM ID: 101235597 Publication Model: eCollection Cited Medium: Print ISSN: 1726-913X (Print) Linking ISSN: 1726913X NLM ISO Abbreviation: Int J Endocrinol Metab Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2022- : ['s-Hertogenbosch, The Netherlands] : Brieflands Original Publication: Tehran : Endocrine Research Center, [2003]- |
| مستخلص: | Background: Diabetes refers to a group of metabolic diseases with blood glucose of higher than normal ranges. Furthermore, n-3 polyunsaturated fatty acids are necessary for the regulation of the activity of human function. The effect of n-3 PUFA on diabetes has been investigated in animal studies, yet, the exact amount has not been set, to date. Irisin, as a new myokine, is released from skeletal muscle and Irisin levels decrease as a result of physical inactivity, overweightness, and obesity. Also, the reduction of serum irisin level is associated with development of insulin resistance and type 2 diabetes. This study was performed to assess the effects of n-3 PUFA supplementation on serum irisin level in patients with diabetes. Methods: This randomized clinical trial included 43 patients with type 2 diabetes (21 patients in the placebo group and 22 patients in the n-3 PUFA supplement group). They were randomized to groups, one receiving 10 weeks of either n-3 PUFA supplement and the other the placebo (1250 mg capsule, three times per day). Samples were also matched by age, gender, and body mass index (BMI) in the 2 groups. Anthropometric measurements, demographic information and dietary intakes were obtained both before and after the intervention. Serum irisin levels were measured before and after the intervention using human irisin enzyme linked immunosorbent assay (ELISA) kit. Independent t-test was used to compare the mean outcomes between groups. Results: At baseline, irisin serum levels were not significantly different between the placebo and n-3 PUFA supplementation groups (P > 0.05). However, a significant change was observed between the groups after intervention (P = 0.04). Also there was a significant difference in mean change (after versus before the intervention) (P = 0.05). Compared to the placebo, n-3 PUFA supplementation decreased serum FBS and HbA1C (P = 0.036 and 0.001; respectively). Also, there were significant differences between changes of diastolic blood pressure and HOMA-IR after the intervention between the groups. The duration of illness was not considered as a confounding factor because there was no significant association between irisin level (after versus before the intervention) and the illness duration. Conclusions: The current study indicated that n-3 PUFA supplementation with a dosage of 1250 mg three times per day, resulted in increased serum irisin level of diabetic patients. Competing Interests: Conflict of Interest:The authors declare that they had no conflict of interest. |
| References: | Int J Endocrinol. 2013;2013:746281. (PMID: 24298283) J Diabetes Complications. 2013 Jul-Aug;27(4):365-9. (PMID: 23619195) Eur Rev Med Pharmacol Sci. 2015;19(2):316-21. (PMID: 25683949) Nutr Res Pract. 2014 Apr;8(2):177-82. (PMID: 24741402) Ann Nutr Metab. 2013;63(1-2):60-1. (PMID: 23941905) Lipids Health Dis. 2015 Jan 10;14:1. (PMID: 25575766) Curr Obes Rep. 2014 Feb 02;3:235-41. (PMID: 24818073) Tohoku J Exp Med. 2014;233(2):135-40. (PMID: 24910199) Metabolism. 2013 Aug;62(8):1037-44. (PMID: 23664085) Peptides. 2013 Jan;39:125-30. (PMID: 23219488) PLoS One. 2014 Apr 07;9(4):e94235. (PMID: 24709991) Nature. 2012 Jan 11;481(7382):463-8. (PMID: 22237023) Z Ernahrungswiss. 1998;37 Suppl 1:1-7. (PMID: 9558722) J Clin Endocrinol Metab. 2013 Apr;98(4):E769-78. (PMID: 23436919) PLoS One. 2014 Apr 11;9(4):e94463. (PMID: 24728416) PLoS One. 2013 Sep 02;8(9):e72858. (PMID: 24023786) J Diabetes Res. 2015;2015:359159. (PMID: 26075283) Obes Res. 2003 Oct;11(10 ):1182-91. (PMID: 14569043) J Huazhong Univ Sci Technolog Med Sci. 2009 Apr;29(2):139-43. (PMID: 19399393) Diabetes Res Clin Pract. 2013 Apr;100(1):96-101. (PMID: 23369227) J Appl Physiol (1985). 2007 Sep;103(3):1093-8. (PMID: 17347387) |
| فهرسة مساهمة: | Keywords: Docosahexaenoic Acid (DHA); Eicosapentaenoic Acid (EPA); Irisin; Myokine; Type 2 Diabetes; n-3 Poly Unsaturated Fatty Acids |
| تواريخ الأحداث: | Date Created: 20170825 Latest Revision: 20200930 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC5554612 |
| DOI: | 10.5812/ijem.40614 |
| PMID: | 28835761 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1726-913X |
|---|---|
| DOI: | 10.5812/ijem.40614 |